Esbriet® (pirfenidone) may help preserve more of your lung function by slowing disease progression

Idiopathic pulmonary fibrosis (IPF) is different from other interstitial lung diseases (ILD), or diseases that cause inflammation and scarring of the lungs. Esbriet is specifically studied and approved for use in IPF, which is a certain type of ILD.

Although lung function that is lost cannot be restored, treatment may help maintain more of your lung function by slowing the progression of the disease.

  • In a 1-year clinical study, people who took Esbriet had better breathing capacity compared to those who did not take Esbriet (193 mL difference in forced vital capacity)


Less decline in FVC volume for people taking Esbriet

Forced Vital Capacity while on Esbriet
  • More than twice as many people who took Esbriet had stable lung function (23%) compared to those who did not take Esbriet (10%) at 1 year
  • One 72-week study showed similar results
  • Another 72-week study did not show a significant difference between people who took Esbriet and those who did not 

How lung function was measured

In the clinical studies, the effect of Esbriet on lung function (how well the lungs work) was measured by forced vital capacity (FVC). FVC measures the amount of air you can exhale with force after you inhale as deeply as possible.



Key facts about Esbriet

  • Esbriet was FDA approved based on 3 clinical studies that evaluated its safety and how well it worked in more than 1,400 patients
    • More than 170 of these patients were treated with Esbriet for over 5 years in clinical studies
  • Esbriet is proven to help preserve lung function for some people with IPF
  • Esbriet may cause serious side effects
  • Esbriet has been used in more than 50,000 patients worldwide
Woman and granddaughter

Important things to keep in mind with IPF treatment

  • IPF is progressive, so slowing its decline can be an important goal of treatment
  • Starting and staying on Esbriet treatment as prescribed by your doctor can be an important way to help preserve more of the lung function you have today by slowing disease progression
  • Esbriet has been shown to preserve lung function. Therefore, once you begin taking Esbriet, you may not “feel” different, because Esbriet does not treat the symptoms of IPF and does not reverse the scarring in your lungs
  • IPF worsens at different rates in different people. With or without Esbriet, lung function may continue to decline. Remember, the goal is to slow the decline. Your doctor will conduct lung function tests to measure how IPF is affecting your lungs over time


Want to learn more about Esbriet?

Check out these frequently asked questions > 

If you have questions about Esbriet, talk to your doctor. 

You can also reach out to our 24-Hour Nurse Support Line, 24 hours a day, 7 days a week, by calling 1-844-693-7274 and pressing 1 to speak with a nurse.

*The nurse support line does not offer medical advice. If you have questions about your health or treatment, you are encouraged to contact your healthcare provider


Taking Esbriet

See dosing information, tips for sticking to a schedule, and ways to manage possible side effects.


Questions about Esbriet

See a list of answers to frequently asked questions about IPF treatment with Esbriet.


Esbriet Inspiration Program

Receive ongoing support and materials from the Esbriet® Inspiration Program™ to help you manage IPF.